View Financial HealthLevel Bio 配当と自社株買い配当金 基準チェック /06Level Bio配当金を支払った記録がありません。主要情報n/a配当利回り0%バイバック利回り総株主利回り0%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesBoard Change • May 20No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 6 experienced directors. 2 highly experienced directors. No independent directors (7 non-independent directors). Director Mikael Kubista was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Apr 02Devyser AB completed the acquisition of CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO).Devyser AB agreed to acquire CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) for SEK 12.2 million on February 11, 2026. The consideration consists of common equity of Devyser AB having a value of SEK 12.2 million to be issued for common equity of CyberGene AB. As part of consideration, SEK 12.2 million is paid towards common equity of CyberGene AB. The acquisition is fully financed through a directed issue of new shares in Devyser to the seller, to be paid by way of set-off against the seller’s claim on payment of the purchase price. Based on the authorization granted by the Annual General Meeting on 14 May 2025, the Board of Directors intends, subject to receipt of the necessary clearance from the Inspectorate of Strategic Products, to resolve upon an issue of new shares in Devyser. Level Bio AB (publ), as the seller of Cybergene, will be entitled to subscribe for the new shares. The transaction is subject to approval by regulatory board / committee. The expected completion of the transaction is April 1, 2026. The acquisition strengthens Devyser’s customer offering within the aneuploidy segment and is expected to have a positive impact on Devyser’s gross profit and gross margin. Devyser AB completed the acquisition of CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) on April 1, 2026. The acquisition was conditional upon the receipt of all necessary clearances, approvals, decisions and other actions from the Inspectorate of Strategic Products under the Swedish Screening of Foreign Direct Investments Act. This closing condition has been fulfilled on April 1, 2026. The acquisition is consolidated from and including April 1, 2026 and is expected to have a positive impact on Devyser’s gross profit as well as EBIT.お知らせ • Feb 12Devyser AB agreed to acquire CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) for SEK 12.2 million.Devyser AB agreed to acquire CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) for SEK 12.2 million on February 11, 2026. The consideration consists of common equity of Devyser AB having a value of SEK 12.2 million to be issued for common equity of CyberGene AB. As part of consideration, SEK 12.2 million is paid towards common equity of CyberGene AB. The transaction is subject to approval by regulatory board / committee. The expected completion of the transaction is April 1, 2026. The acquisition strengthens Devyser’s customer offering within the aneuploidy segment and is expected to have a positive impact on Devyser’s gross profit and gross margin. The acquisition is fully financed through a directed issue of new shares in Devyser to the seller, to be paid by way of set-off against the seller’s claim on payment of the purchase price. Based on the authorization granted by the Annual General Meeting on 14 May 2025, the Board of Directors intends, subject to receipt of the necessary clearance from the Inspectorate of Strategic Products, to resolve upon an issue of new shares in Devyser. Level Bio AB (publ), as the seller of Cybergene, will be entitled to subscribe for the new shares.Reported Earnings • Apr 26First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: kr5.67m (down 33% from 1Q 2023). Net loss: kr2.46m (loss widened 343% from 1Q 2023).お知らせ • Mar 27AlphaHelix Molecular Diagnostics AB (publ) to Report Q1, 2024 Results on Apr 25, 2024AlphaHelix Molecular Diagnostics AB (publ) announced that they will report Q1, 2024 results on Apr 25, 2024お知らせ • Mar 20AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Apr 18, 2024AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Apr 18, 2024.Reported Earnings • Feb 25Full year 2023 earnings released: kr0.15 loss per share (vs kr0.035 loss in FY 2022)Full year 2023 results: kr0.15 loss per share (further deteriorated from kr0.035 loss in FY 2022). Revenue: kr26.6m (down 23% from FY 2022). Net loss: kr9.48m (loss widened 326% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance.お知らせ • Jan 24AlphaHelix Molecular Diagnostics AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2024AlphaHelix Molecular Diagnostics AB (publ) announced that they will report fiscal year 2023 results on Feb 22, 2024New Risk • Oct 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr4.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr4.9m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (kr43.6m market cap, or US$3.91m). Minor Risk Revenue is less than US$5m (kr30m revenue, or US$2.7m).お知らせ • Sep 27AlphaHelix Molecular Diagnostics AB (publ) to Report Q3, 2023 Results on Oct 26, 2023AlphaHelix Molecular Diagnostics AB (publ) announced that they will report Q3, 2023 results on Oct 26, 2023Reported Earnings • Aug 28Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr5.39m (down 6.3% from 2Q 2022). Net loss: kr2.36m (loss narrowed 2.4% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 28% per year, which means it has not declined as severely as earnings.お知らせ • Jul 26AlphaHelix Molecular Diagnostics AB (publ) to Report Q2, 2023 Results on Aug 24, 2023AlphaHelix Molecular Diagnostics AB (publ) announced that they will report Q2, 2023 results on Aug 24, 2023お知らせ • May 31AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Jun 29, 2023AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Jun 29, 2023.Reported Earnings • Apr 20First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr8.48m (down 35% from 1Q 2022). Net loss: kr554.0k (down 139% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.Reported Earnings • Feb 24Full year 2022 earnings released: kr0.035 loss per share (vs kr0.087 profit in FY 2021)Full year 2022 results: kr0.035 loss per share (down from kr0.087 profit in FY 2021). Revenue: kr34.7m (down 21% from FY 2021). Net loss: kr2.22m (down 143% from profit in FY 2021). Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 4% per year.お知らせ • Jan 18AlphaHelix Molecular Diagnostics AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023AlphaHelix Molecular Diagnostics AB (publ) announced that they will report fiscal year 2022 results on Feb 16, 2023Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Joakim Grånemo was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 30Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr5.63m (down 16% from 3Q 2021). Net loss: kr1.19m (loss widened kr1.09m from 3Q 2021).Valuation Update With 7 Day Price Move • Jul 27Investor sentiment improved over the past weekAfter last week's 19% share price gain to kr1.13, the stock trades at a trailing P/E ratio of 14.4x. Average trailing P/E is 43x in the Life Sciences industry in Sweden. Total returns to shareholders of 82% over the past three years.分析記事 • Jun 02Do AlphaHelix Molecular Diagnostics's (NGM:ALPH) Earnings Warrant Your Attention?It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...Reported Earnings • Apr 27First quarter 2022 earnings released: EPS: kr0.022 (vs kr0.031 in 1Q 2021)First quarter 2022 results: EPS: kr0.022 (down from kr0.031 in 1Q 2021). Revenue: kr13.1m (up 39% from 1Q 2021). Net income: kr1.42m (down 12% from 1Q 2021). Profit margin: 11% (down from 17% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Neven Zoric was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 22First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: kr13.2m (up 40% from 1Q 2021). Net income: kr1.42m (down 12% from 1Q 2021). Profit margin: 11% (down from 17% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has only increased by 38% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Mar 23Investor sentiment improved over the past weekAfter last week's 17% share price gain to kr1.85, the stock trades at a trailing P/E ratio of 22.8x. Average trailing P/E is 56x in the Life Sciences industry in Sweden. Total returns to shareholders of 160% over the past three years.Valuation Update With 7 Day Price Move • Feb 24Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to kr1.78, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 43x in the Life Sciences industry in Sweden. Total returns to shareholders of 122% over the past three years.Reported Earnings • Feb 18Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: kr0.081 (up from kr0.029 in FY 2020). Revenue: kr44.7m (up 90% from FY 2020). Net income: kr5.16m (up 241% from FY 2020). Profit margin: 12% (up from 6.4% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has only increased by 44% per year, which means it is significantly lagging earnings growth.分析記事 • Feb 10Should You Be Adding AlphaHelix Molecular Diagnostics (NGM:ALPH) To Your Watchlist Today?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Valuation Update With 7 Day Price Move • Jan 24Investor sentiment deteriorated over the past weekAfter last week's 26% share price decline to kr1.96, the stock trades at a trailing P/E ratio of 25.9x. Average trailing P/E is 45x in the Life Sciences industry in Sweden. Total returns to shareholders of 141% over the past three years.Valuation Update With 7 Day Price Move • Jan 04Investor sentiment improved over the past weekAfter last week's 15% share price gain to kr2.88, the stock trades at a trailing P/E ratio of 38.1x. Average trailing P/E is 60x in the Life Sciences industry in Sweden. Total returns to shareholders of 224% over the past three years.分析記事 • Nov 03I Ran A Stock Scan For Earnings Growth And AlphaHelix Molecular Diagnostics (NGM:ALPH) Passed With EaseSome have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...Reported Earnings • Nov 01Third quarter 2021 earnings releasedThe company reported a mediocre third quarter result with weaker earnings and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: kr6.96m (up 42% from 3Q 2020). Net loss: kr107.0k (down 168% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 127% per year but the company’s share price has only increased by 43% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Sep 14Investor sentiment improved over the past weekAfter last week's 25% share price gain to kr3.24, the stock trades at a trailing P/E ratio of 37.2x. Average trailing P/E is 50x in the Life Sciences industry in Sweden. Total returns to shareholders of 220% over the past three years.Valuation Update With 7 Day Price Move • Aug 30Investor sentiment improved over the past weekAfter last week's 16% share price gain to kr2.69, the stock trades at a trailing P/E ratio of 30.9x. Average trailing P/E is 50x in the Life Sciences industry in Sweden. Total returns to shareholders of 180% over the past three years.分析記事 • Aug 18AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH) Stock Rockets 35% As Investors Are Less Pessimistic Than ExpectedDespite an already strong run, AlphaHelix Molecular Diagnostics AB (publ) ( NGM:ALPH ) shares have been powering on...Reported Earnings • Aug 18Second quarter 2021 earnings released: EPS kr0.056 (vs kr0.014 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: kr15.8m (up 153% from 2Q 2020). Net income: kr3.54m (up 363% from 2Q 2020). Profit margin: 22% (up from 12% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 117% per year but the company’s share price has only increased by 36% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Aug 04Investor sentiment improved over the past weekAfter last week's 26% share price gain to kr2.23, the stock trades at a trailing P/E ratio of 51.4x. Average trailing P/E is 48x in the Life Sciences industry in Sweden. Total returns to shareholders of 133% over the past three years.Valuation Update With 7 Day Price Move • Jul 15Investor sentiment improved over the past weekAfter last week's 17% share price gain to kr1.89, the stock trades at a trailing P/E ratio of 43.6x. Average trailing P/E is 47x in the Life Sciences industry in Sweden. Total returns to shareholders of 81% over the past three years.Valuation Update With 7 Day Price Move • Jun 15Investor sentiment improved over the past weekAfter last week's 19% share price gain to kr1.82, the stock trades at a trailing P/E ratio of 42x. Average trailing P/E is 45x in the Life Sciences industry in Sweden. Total returns to shareholders of 102% over the past three years.Valuation Update With 7 Day Price Move • May 26Investor sentiment improved over the past weekAfter last week's 21% share price gain to kr1.67, the stock trades at a trailing P/E ratio of 38.5x. Average trailing P/E is 41x in the Life Sciences industry in Sweden. Total returns to shareholders of 83% over the past three years.Reported Earnings • Apr 25First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: kr9.46m (up 50% from 1Q 2020). Net income: kr1.61m (up 93% from 1Q 2020). Profit margin: 17% (up from 13% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 106% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Mar 09Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to kr1.40, the stock is trading at a trailing P/E ratio of 48.8x, down from the previous P/E ratio of 59.2x. This compares to an average P/E of 49x in the Life Sciences industry in Sweden. Total returns to shareholders over the past three years are 46%.分析記事 • Mar 07Do Its Financials Have Any Role To Play In Driving AlphaHelix Molecular Diagnostics AB (publ)'s (NGM:ALPH) Stock Up Recently?Most readers would already be aware that AlphaHelix Molecular Diagnostics' (NGM:ALPH) stock increased significantly by...Is New 90 Day High Low • Feb 09New 90-day high: kr1.49The company is up 52% from its price of kr0.98 on 10 November 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 27% over the same period.Is New 90 Day High Low • Jan 21New 90-day high: kr1.44The company is up 13% from its price of kr1.27 on 23 October 2020. The Swedish market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 4.0% over the same period.Valuation Update With 7 Day Price Move • Jan 20Investor sentiment improved over the past weekAfter last week's 21% share price gain to kr1.29, the stock is trading at a trailing P/E ratio of 57.3x, up from the previous P/E ratio of 47.6x. This compares to an average P/E of 52x in the Life Sciences industry in Sweden. Total returns to shareholders over the past three years are 27%.Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improved over the past weekAfter last week's 36% share price gain to kr1.31, the stock is trading at a trailing P/E ratio of 39.4x, up from the previous P/E ratio of 28.8x. This compares to an average P/E of 46x in the Life Sciences industry in Sweden. Total returns to shareholders over the past three years are 19%.Valuation Update With 7 Day Price Move • Dec 22Investor sentiment improved over the past weekAfter last week's 17% share price gain to kr1.05, the stock is trading at a trailing P/E ratio of 31.5x, up from the previous P/E ratio of 26.9x. This compares to an average P/E of 44x in the Life Sciences industry in Sweden. Total return to shareholders over the past three years is a loss of 12%.Is New 90 Day High Low • Dec 01New 90-day low: kr0.82The company is down 37% from its price of kr1.30 on 02 September 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 4.0% over the same period.分析記事 • Nov 22Declining Stock and Decent Financials: Is The Market Wrong About AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH)?It is hard to get excited after looking at AlphaHelix Molecular Diagnostics' (NGM:ALPH) recent performance, when its...Valuation Update With 7 Day Price Move • Nov 03Market pulls back on stock over the past weekAfter last week's 20% share price decline to kr1.09, the stock is trading at a trailing P/E ratio of 63x, down from the previous P/E ratio of 78.5x. This compares to an average P/E of 56x in the Life Sciences industry in Sweden. Total return to shareholders over the past three years is a loss of 11%.Is New 90 Day High Low • Nov 03New 90-day low: kr1.09The company is down 26% from its price of kr1.48 on 05 August 2020. The Swedish market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 6.0% over the same period.Valuation Update With 7 Day Price Move • Oct 26Market bids up stock over the past weekAfter last week's 18% share price gain to kr1.38, the stock is trading at a trailing P/E ratio of 79.7x, up from the previous P/E ratio of 67.6x. This compares to an average P/E of 58x in the Life Sciences industry in Sweden. Total return to shareholders over the past three years is a loss of 8.6%.Is New 90 Day High Low • Oct 13New 90-day low: kr1.20The company is down 26% from its price of kr1.62 on 14 July 2020. The Swedish market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 25% over the same period.お知らせ • Jul 30Xanadu Technologies AB, Tataa Biocenter AB and Active Healthtech Nordic AB acquired a 13.17% stake in AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH) from Labkompaniet AB.Xanadu Technologies AB, Tataa Biocenter AB and Active Healthtech Nordic AB acquired a 13.17% stake in AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH) from Labkompaniet AB on May 6, 2020. Under the terms, 7 million shares were sold by Labkompaniet. Labkompaniet decreased its stake from 52.68% to 39.51%. Active Healthtech's will own 6.58%. Xanadu Technologies AB, Tataa Biocenter AB and Active Healthtech Nordic AB completed the acquisition of a 13.17% stake in AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH) from Labkompaniet AB on May 6, 2020.決済の安定と成長配当データの取得安定した配当: LEVBIOの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: LEVBIOの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Level Bio 配当利回り対市場LEVBIO 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (LEVBIO)n/a市場下位25% (SE)1.8%市場トップ25% (SE)4.3%業界平均 (Life Sciences)0.8%アナリスト予想 (LEVBIO) (最長3年)n/a注目すべき配当: LEVBIOは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: LEVBIOは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: LEVBIOの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: LEVBIOが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YSE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/11 21:01終値2026/06/11 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Level Bio AB (publ) 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 20No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 6 experienced directors. 2 highly experienced directors. No independent directors (7 non-independent directors). Director Mikael Kubista was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Apr 02Devyser AB completed the acquisition of CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO).Devyser AB agreed to acquire CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) for SEK 12.2 million on February 11, 2026. The consideration consists of common equity of Devyser AB having a value of SEK 12.2 million to be issued for common equity of CyberGene AB. As part of consideration, SEK 12.2 million is paid towards common equity of CyberGene AB. The acquisition is fully financed through a directed issue of new shares in Devyser to the seller, to be paid by way of set-off against the seller’s claim on payment of the purchase price. Based on the authorization granted by the Annual General Meeting on 14 May 2025, the Board of Directors intends, subject to receipt of the necessary clearance from the Inspectorate of Strategic Products, to resolve upon an issue of new shares in Devyser. Level Bio AB (publ), as the seller of Cybergene, will be entitled to subscribe for the new shares. The transaction is subject to approval by regulatory board / committee. The expected completion of the transaction is April 1, 2026. The acquisition strengthens Devyser’s customer offering within the aneuploidy segment and is expected to have a positive impact on Devyser’s gross profit and gross margin. Devyser AB completed the acquisition of CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) on April 1, 2026. The acquisition was conditional upon the receipt of all necessary clearances, approvals, decisions and other actions from the Inspectorate of Strategic Products under the Swedish Screening of Foreign Direct Investments Act. This closing condition has been fulfilled on April 1, 2026. The acquisition is consolidated from and including April 1, 2026 and is expected to have a positive impact on Devyser’s gross profit as well as EBIT.
お知らせ • Feb 12Devyser AB agreed to acquire CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) for SEK 12.2 million.Devyser AB agreed to acquire CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) for SEK 12.2 million on February 11, 2026. The consideration consists of common equity of Devyser AB having a value of SEK 12.2 million to be issued for common equity of CyberGene AB. As part of consideration, SEK 12.2 million is paid towards common equity of CyberGene AB. The transaction is subject to approval by regulatory board / committee. The expected completion of the transaction is April 1, 2026. The acquisition strengthens Devyser’s customer offering within the aneuploidy segment and is expected to have a positive impact on Devyser’s gross profit and gross margin. The acquisition is fully financed through a directed issue of new shares in Devyser to the seller, to be paid by way of set-off against the seller’s claim on payment of the purchase price. Based on the authorization granted by the Annual General Meeting on 14 May 2025, the Board of Directors intends, subject to receipt of the necessary clearance from the Inspectorate of Strategic Products, to resolve upon an issue of new shares in Devyser. Level Bio AB (publ), as the seller of Cybergene, will be entitled to subscribe for the new shares.
Reported Earnings • Apr 26First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: kr5.67m (down 33% from 1Q 2023). Net loss: kr2.46m (loss widened 343% from 1Q 2023).
お知らせ • Mar 27AlphaHelix Molecular Diagnostics AB (publ) to Report Q1, 2024 Results on Apr 25, 2024AlphaHelix Molecular Diagnostics AB (publ) announced that they will report Q1, 2024 results on Apr 25, 2024
お知らせ • Mar 20AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Apr 18, 2024AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Apr 18, 2024.
Reported Earnings • Feb 25Full year 2023 earnings released: kr0.15 loss per share (vs kr0.035 loss in FY 2022)Full year 2023 results: kr0.15 loss per share (further deteriorated from kr0.035 loss in FY 2022). Revenue: kr26.6m (down 23% from FY 2022). Net loss: kr9.48m (loss widened 326% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance.
お知らせ • Jan 24AlphaHelix Molecular Diagnostics AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2024AlphaHelix Molecular Diagnostics AB (publ) announced that they will report fiscal year 2023 results on Feb 22, 2024
New Risk • Oct 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr4.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr4.9m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (kr43.6m market cap, or US$3.91m). Minor Risk Revenue is less than US$5m (kr30m revenue, or US$2.7m).
お知らせ • Sep 27AlphaHelix Molecular Diagnostics AB (publ) to Report Q3, 2023 Results on Oct 26, 2023AlphaHelix Molecular Diagnostics AB (publ) announced that they will report Q3, 2023 results on Oct 26, 2023
Reported Earnings • Aug 28Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr5.39m (down 6.3% from 2Q 2022). Net loss: kr2.36m (loss narrowed 2.4% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 28% per year, which means it has not declined as severely as earnings.
お知らせ • Jul 26AlphaHelix Molecular Diagnostics AB (publ) to Report Q2, 2023 Results on Aug 24, 2023AlphaHelix Molecular Diagnostics AB (publ) announced that they will report Q2, 2023 results on Aug 24, 2023
お知らせ • May 31AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Jun 29, 2023AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Jun 29, 2023.
Reported Earnings • Apr 20First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr8.48m (down 35% from 1Q 2022). Net loss: kr554.0k (down 139% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Feb 24Full year 2022 earnings released: kr0.035 loss per share (vs kr0.087 profit in FY 2021)Full year 2022 results: kr0.035 loss per share (down from kr0.087 profit in FY 2021). Revenue: kr34.7m (down 21% from FY 2021). Net loss: kr2.22m (down 143% from profit in FY 2021). Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 4% per year.
お知らせ • Jan 18AlphaHelix Molecular Diagnostics AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023AlphaHelix Molecular Diagnostics AB (publ) announced that they will report fiscal year 2022 results on Feb 16, 2023
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Joakim Grånemo was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 30Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr5.63m (down 16% from 3Q 2021). Net loss: kr1.19m (loss widened kr1.09m from 3Q 2021).
Valuation Update With 7 Day Price Move • Jul 27Investor sentiment improved over the past weekAfter last week's 19% share price gain to kr1.13, the stock trades at a trailing P/E ratio of 14.4x. Average trailing P/E is 43x in the Life Sciences industry in Sweden. Total returns to shareholders of 82% over the past three years.
分析記事 • Jun 02Do AlphaHelix Molecular Diagnostics's (NGM:ALPH) Earnings Warrant Your Attention?It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
Reported Earnings • Apr 27First quarter 2022 earnings released: EPS: kr0.022 (vs kr0.031 in 1Q 2021)First quarter 2022 results: EPS: kr0.022 (down from kr0.031 in 1Q 2021). Revenue: kr13.1m (up 39% from 1Q 2021). Net income: kr1.42m (down 12% from 1Q 2021). Profit margin: 11% (down from 17% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Neven Zoric was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 22First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: kr13.2m (up 40% from 1Q 2021). Net income: kr1.42m (down 12% from 1Q 2021). Profit margin: 11% (down from 17% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has only increased by 38% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Mar 23Investor sentiment improved over the past weekAfter last week's 17% share price gain to kr1.85, the stock trades at a trailing P/E ratio of 22.8x. Average trailing P/E is 56x in the Life Sciences industry in Sweden. Total returns to shareholders of 160% over the past three years.
Valuation Update With 7 Day Price Move • Feb 24Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to kr1.78, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 43x in the Life Sciences industry in Sweden. Total returns to shareholders of 122% over the past three years.
Reported Earnings • Feb 18Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: kr0.081 (up from kr0.029 in FY 2020). Revenue: kr44.7m (up 90% from FY 2020). Net income: kr5.16m (up 241% from FY 2020). Profit margin: 12% (up from 6.4% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has only increased by 44% per year, which means it is significantly lagging earnings growth.
分析記事 • Feb 10Should You Be Adding AlphaHelix Molecular Diagnostics (NGM:ALPH) To Your Watchlist Today?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Valuation Update With 7 Day Price Move • Jan 24Investor sentiment deteriorated over the past weekAfter last week's 26% share price decline to kr1.96, the stock trades at a trailing P/E ratio of 25.9x. Average trailing P/E is 45x in the Life Sciences industry in Sweden. Total returns to shareholders of 141% over the past three years.
Valuation Update With 7 Day Price Move • Jan 04Investor sentiment improved over the past weekAfter last week's 15% share price gain to kr2.88, the stock trades at a trailing P/E ratio of 38.1x. Average trailing P/E is 60x in the Life Sciences industry in Sweden. Total returns to shareholders of 224% over the past three years.
分析記事 • Nov 03I Ran A Stock Scan For Earnings Growth And AlphaHelix Molecular Diagnostics (NGM:ALPH) Passed With EaseSome have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...
Reported Earnings • Nov 01Third quarter 2021 earnings releasedThe company reported a mediocre third quarter result with weaker earnings and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: kr6.96m (up 42% from 3Q 2020). Net loss: kr107.0k (down 168% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 127% per year but the company’s share price has only increased by 43% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Sep 14Investor sentiment improved over the past weekAfter last week's 25% share price gain to kr3.24, the stock trades at a trailing P/E ratio of 37.2x. Average trailing P/E is 50x in the Life Sciences industry in Sweden. Total returns to shareholders of 220% over the past three years.
Valuation Update With 7 Day Price Move • Aug 30Investor sentiment improved over the past weekAfter last week's 16% share price gain to kr2.69, the stock trades at a trailing P/E ratio of 30.9x. Average trailing P/E is 50x in the Life Sciences industry in Sweden. Total returns to shareholders of 180% over the past three years.
分析記事 • Aug 18AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH) Stock Rockets 35% As Investors Are Less Pessimistic Than ExpectedDespite an already strong run, AlphaHelix Molecular Diagnostics AB (publ) ( NGM:ALPH ) shares have been powering on...
Reported Earnings • Aug 18Second quarter 2021 earnings released: EPS kr0.056 (vs kr0.014 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: kr15.8m (up 153% from 2Q 2020). Net income: kr3.54m (up 363% from 2Q 2020). Profit margin: 22% (up from 12% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 117% per year but the company’s share price has only increased by 36% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Aug 04Investor sentiment improved over the past weekAfter last week's 26% share price gain to kr2.23, the stock trades at a trailing P/E ratio of 51.4x. Average trailing P/E is 48x in the Life Sciences industry in Sweden. Total returns to shareholders of 133% over the past three years.
Valuation Update With 7 Day Price Move • Jul 15Investor sentiment improved over the past weekAfter last week's 17% share price gain to kr1.89, the stock trades at a trailing P/E ratio of 43.6x. Average trailing P/E is 47x in the Life Sciences industry in Sweden. Total returns to shareholders of 81% over the past three years.
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment improved over the past weekAfter last week's 19% share price gain to kr1.82, the stock trades at a trailing P/E ratio of 42x. Average trailing P/E is 45x in the Life Sciences industry in Sweden. Total returns to shareholders of 102% over the past three years.
Valuation Update With 7 Day Price Move • May 26Investor sentiment improved over the past weekAfter last week's 21% share price gain to kr1.67, the stock trades at a trailing P/E ratio of 38.5x. Average trailing P/E is 41x in the Life Sciences industry in Sweden. Total returns to shareholders of 83% over the past three years.
Reported Earnings • Apr 25First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: kr9.46m (up 50% from 1Q 2020). Net income: kr1.61m (up 93% from 1Q 2020). Profit margin: 17% (up from 13% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 106% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Mar 09Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to kr1.40, the stock is trading at a trailing P/E ratio of 48.8x, down from the previous P/E ratio of 59.2x. This compares to an average P/E of 49x in the Life Sciences industry in Sweden. Total returns to shareholders over the past three years are 46%.
分析記事 • Mar 07Do Its Financials Have Any Role To Play In Driving AlphaHelix Molecular Diagnostics AB (publ)'s (NGM:ALPH) Stock Up Recently?Most readers would already be aware that AlphaHelix Molecular Diagnostics' (NGM:ALPH) stock increased significantly by...
Is New 90 Day High Low • Feb 09New 90-day high: kr1.49The company is up 52% from its price of kr0.98 on 10 November 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 27% over the same period.
Is New 90 Day High Low • Jan 21New 90-day high: kr1.44The company is up 13% from its price of kr1.27 on 23 October 2020. The Swedish market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 4.0% over the same period.
Valuation Update With 7 Day Price Move • Jan 20Investor sentiment improved over the past weekAfter last week's 21% share price gain to kr1.29, the stock is trading at a trailing P/E ratio of 57.3x, up from the previous P/E ratio of 47.6x. This compares to an average P/E of 52x in the Life Sciences industry in Sweden. Total returns to shareholders over the past three years are 27%.
Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improved over the past weekAfter last week's 36% share price gain to kr1.31, the stock is trading at a trailing P/E ratio of 39.4x, up from the previous P/E ratio of 28.8x. This compares to an average P/E of 46x in the Life Sciences industry in Sweden. Total returns to shareholders over the past three years are 19%.
Valuation Update With 7 Day Price Move • Dec 22Investor sentiment improved over the past weekAfter last week's 17% share price gain to kr1.05, the stock is trading at a trailing P/E ratio of 31.5x, up from the previous P/E ratio of 26.9x. This compares to an average P/E of 44x in the Life Sciences industry in Sweden. Total return to shareholders over the past three years is a loss of 12%.
Is New 90 Day High Low • Dec 01New 90-day low: kr0.82The company is down 37% from its price of kr1.30 on 02 September 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 4.0% over the same period.
分析記事 • Nov 22Declining Stock and Decent Financials: Is The Market Wrong About AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH)?It is hard to get excited after looking at AlphaHelix Molecular Diagnostics' (NGM:ALPH) recent performance, when its...
Valuation Update With 7 Day Price Move • Nov 03Market pulls back on stock over the past weekAfter last week's 20% share price decline to kr1.09, the stock is trading at a trailing P/E ratio of 63x, down from the previous P/E ratio of 78.5x. This compares to an average P/E of 56x in the Life Sciences industry in Sweden. Total return to shareholders over the past three years is a loss of 11%.
Is New 90 Day High Low • Nov 03New 90-day low: kr1.09The company is down 26% from its price of kr1.48 on 05 August 2020. The Swedish market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 6.0% over the same period.
Valuation Update With 7 Day Price Move • Oct 26Market bids up stock over the past weekAfter last week's 18% share price gain to kr1.38, the stock is trading at a trailing P/E ratio of 79.7x, up from the previous P/E ratio of 67.6x. This compares to an average P/E of 58x in the Life Sciences industry in Sweden. Total return to shareholders over the past three years is a loss of 8.6%.
Is New 90 Day High Low • Oct 13New 90-day low: kr1.20The company is down 26% from its price of kr1.62 on 14 July 2020. The Swedish market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 25% over the same period.
お知らせ • Jul 30Xanadu Technologies AB, Tataa Biocenter AB and Active Healthtech Nordic AB acquired a 13.17% stake in AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH) from Labkompaniet AB.Xanadu Technologies AB, Tataa Biocenter AB and Active Healthtech Nordic AB acquired a 13.17% stake in AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH) from Labkompaniet AB on May 6, 2020. Under the terms, 7 million shares were sold by Labkompaniet. Labkompaniet decreased its stake from 52.68% to 39.51%. Active Healthtech's will own 6.58%. Xanadu Technologies AB, Tataa Biocenter AB and Active Healthtech Nordic AB completed the acquisition of a 13.17% stake in AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH) from Labkompaniet AB on May 6, 2020.